CD38-directed Antibody Interactions [MoA] - N0000192335

  1. Home
  2. Pharmacologic Class Index
  3. CD38-directed Antibody Interactions [MoA] - N0000192335

Pharmacologic Class Information

Pharmacologic Code N0000192335
Pharmacologic Name CD38-directed Antibody Interactions
Pharmacologic Uses
  • CD38-directed cytolytic antibody
Pharmacologic Concept Mechanisms of Action - [MoA]
Pharmacologic Concept Description This concept refers to the mechanism of action pharmacologic action at the receptor, membrane, or tissue level. In MED-RT, molecular, subcellular, or cellular effects of drug generic ingredients, organized into a chemical function classification hierarchy, beneath the "Cellular or Molecular Interactions" concept.

NDC Products with CD38-directed Antibody Interactions

The table contains 5 products whose active ingredient are classified under the same pharmacologic class CD38-directed Antibody Interactions [MoA].

NDC Proprietary Name Non-Proprietary Name Dosage Form Route Name Company Name Status
0024-0654Sarclisa Non-Proprietary Name: IsatuximabInjection, Solution, ConcentrateIntravenousSanof-aventis U.s. LlcACTIVE
0024-0656Sarclisa Non-Proprietary Name: IsatuximabInjection, Solution, ConcentrateIntravenousSanof-aventis U.s. LlcACTIVE
57894-502Darzalex Non-Proprietary Name: DaratumumabInjection, Solution, ConcentrateIntravenousJanssen Biotech, Inc.ACTIVE
57894-503Darzalex Faspro Non-Proprietary Name: Daratumumab And Hyaluronidase-fihj (human Recombinant)InjectionSubcutaneousJanssen Biotech, Inc.ACTIVE
57894-505Darzalex Iv Non-Proprietary Name: DaratumumabInjection, Solution, ConcentrateIntravenousJanssen Biotech, Inc.ACTIVE